AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-Driven `Drug Delivery` and `Drug Discovery`

剂泰医药凭借在AI驱动药物递送和药物发现领域的出色表现、企业快速发展及卓越的创新领导力等优势，入选“创新先锋榜”的“领跑者（Front-Runners)”。

剂泰医药荣登“2023中国生物医药领跑者100”榜单

9月26日，由张江集团主办，张江AI新药研发联盟、美迪西、晶泰科技共同承办的 “引领新方向 聚AI迎未来——2023张江AI智药论坛”在张江科学会堂成功举行。剂泰医药作为AI+药物递送行业的领军企业正式加入“张江AI新药研发联盟”，联合创始人兼CEO赖才达博士在论坛上发表了题为“AI+药物递送，突破CGT产业研发瓶颈”的演讲，分享基因治疗药物研发面临的挑战。<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/67bb51f10d7e7b20725fabba7f2ea69c.png" width="617px" height="329.854px" style="width:617px;height:329.854px"/></div>CGT产业引领药物革命随着医药技术不断迭代升级，核酸药物、基因治疗等新形态药物逐渐发挥越来越重要的作用，有望成为继小分子药物和抗体药物后的第三大药物，引发新一代制药行业科技浪潮。中国作为生物医药的中坚力量，正在积极推动这一领域的科技创新和产业发展。9月18日，上海市科学技术委员会、上海市经济和信息化委员会、上海市卫生健康委员会印发了《上海市促进基因治疗科技创新与产业发展行动方案（2023-2025）》，以推动基因治疗与细胞治疗协同发展，加快打造生物医药科技创新“核爆点”和产业发展“集聚区”。而在早前的9月8日，北京市人民政府办公厅也印发了《北京市促进未来产业创新发展实施方案》，其中强调要重点发展基因技术、细胞治疗与再生医学、脑科学与脑机接口、合成生物等细分产业。然而核酸药物、mRNA疫苗、基因编辑等领域的研发面临一个瓶颈问题，即优化药物本身和普通给药系统很难解决成药性的问题，递送技术成为这些新技术不可分割的一部分。其中递送mRNA疫苗的脂质纳米颗粒（LNP）就是人类这次抗击新冠的关键技术之一。与此同时，AI技术与生物医药的融合也在不断提速，AI对制药领域的赋能逐渐步入深水区。以AI驱动RNA药物研发为代表的新一代疗法有望满足全球患者未被满足的医疗需求。AI+药物递送，突破CGT产业研发瓶颈AI驱动药物开发的价值已越来越受到各界认可，从疾病建模、靶点识别、药物设计到临床试验优化等多个领域，AI正深入推动着药物研发的创新，加快着药物开发的效率和速度。作为“AI+药物递送技术”领域的专家，剂泰医药以AI算法、量子力学和分子动力学模拟以及高通量实验平台等作为底层技术，最大化运用各项交叉学科先进技术，实现高效、精准、安全的多器官靶向药物递送，以此驱动规模化药物发现。<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/6bf955c5453dcdc724b27c6b76409974.png" width="637.667px" height="425px" style="width:637.667px;height:425px"/></div>赖才达博士在会上表示，递送技术是CGT产业 “卡脖子” 的核心环节，所谓递送技术，可以形象地理解为火箭将卫星送到特定位置的技术。药物分子、RNA序列等通过特定的制剂技术可以实现精准递送至有疾病的患病器官、组织和细胞中，从而更好地发挥药效，将疾病细胞编写回健康细胞。为全球患者带来革命性的药物，解决未被满足的临床需求。截至目前，剂泰医药建立了世界领先的端到端mRNA药物发现平台——AiLNP和AiRNA平台，可将药物递送系统效率进行指数级优化。AiRNA以AI算法驱动mRNA密码子优化、二级结构优化及蛋白折叠效率优化，并打造专利UTR库, 增强蛋白表达。通过标准化的工作流程，该平台确保了高质量的mRNA合成。AiLNP平台则构建了具备自主知识产权的mRNA序列设计、LNP递送系统设计一体化的RNA药物开发能力。此外，剂泰医药已成功快速搭建了10余条药物管线，涵盖小分子药物和以mRNA为基础的核酸药物，重点布局在中国及全球临床需求较大的适应症领域，如肿瘤、中枢神经系统及肝病等。此外，剂泰药物还通过共同开发管线或通过技术平台对外授权的合作方式与国内外顶尖药企开展深入合作。赖才达博士表示，加入张江AI新药研发联盟，为剂泰医药拓宽了展示和合作的机会，未来剂泰医药将继续致力于突破基因治疗研发瓶颈，同时也期待与联盟成员们有更多的合作，将AI技术与药物递送的创新结合，不断推动医药产业的革命性发展，为全球患者带来更多希望和健康。

剂泰医药作为AI+药物递送行业的领军企业正式加入“张江AI新药研发联盟”。

剂泰医药加盟张江AI新药研发联盟，AI+药物递送助力CGT产业研发进步

Recently, the largest profiling of the global AI in the Drug Discovery industry made to date has been released in the form of an interactive IT-Platform and associated report by Deep Pharma Intelligence, a leading BioTech market research agency focused on sophisticated analytics, benchmarking and forecasting of emerging and frontier domains in the Pharmaceutical, BioTech and Healthcare industries.The AI in Drug Discovery platform features an interactive database of the Top 100 AI in Drug Discovery Experts, with information-rich profiles on the leading researchers, scientists, entrepreneurs and technologists committed to harnessing the potential of AI to tackle the complex challenges of drug discovery advancement.Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&amp;D, ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/bc918d11436a88cafd649d6e726d62a3.png" width="685" height="405" style="width:685px;height:405px"/></div>Dr. Chen is a member of the National Academy of Engineering, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Controlled Release Society and a member of the Academy of Distinguished Chemical Engineers at the University of Texas at Austin. Dr. Chen holds a B.S. in Chemical Engineering from UT Austin and an M.S. and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology.Before joining METiS, Dr. Chen served as Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped found in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench to Phase III clinical trials and FDA approval, and helped to attract significant investments to the company, including an initial public offering in 2017. Prior to Kala, Dr. Chen helped start and build TransForm Pharmaceuticals, which was acquired by Johnson &amp; Johnson in 2005. She had also held various research positions at AstraZeneca and Merck.

剂泰医药联合创始人兼美国公司总裁、研发负责人陈红敏院士从全球众多创业者中脱颖而出，作为AI制药领域的企业家代表入选该100人名单。

Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&D, ranked on the list ‘TOP 100 LEADERS AI in Drug Discovery’.

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

Dr. Hongming Chen ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’

The 2023 World Artificial Intelligence Conference took place from July 6th to 8th at the Shanghai World Expo Center and the Shanghai World Expo Exhibition &amp; Convention Center. With the theme of &quot;Intelligent Connectivity Generating Future&quot;, this conference is co-sponsored by Shanghai Municipal Government, National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Science and Technology, Cyberspace Administration of China, Chinese Academy of Sciences, Chinese Academy of Engineering, and China Association for Science and Technology. This conference is aimed at giving full play to its important role as “technology leader, application showcase, industry accelerator, and governance council”, bringing together profound wisdom, cutting-edge technologies, industrial trends, and human ecology in the global artificial intelligence field, and promoting the healthy and innovative development of artificial intelligence.On the morning of July 7th, as a representative of AI pharmaceutical companies, Dr. Chris Lai, the co-founder, and CEO of METiS Pharmaceuticals, participated upon invitation in the Financing and Investment sub-Forum of the 2023 World Artificial Intelligence Conference hosted by CICC and themed “Boundless Future, Booming of AIGC”. At the forum, he discussed the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and insights.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/de922bdb70d415b9841dc474220c7a20.png"/></div>The panel discussion was chaired by Zhang Qing, Managing Director of CICC Capital. Dr. Chris Lai, the co-founder and CEO of METiS Pharmaceuticals, John Qu, Global Senior Managing Partner of McKinsey &amp; Company, Han Wei, Chairman of AIForceTech, Ren Peng, Vice President at Perfect World and Head of Strategic Investment Department of, Nyx He, Senior Vice President and Partner at BrainCo, Wang Xiao, Partner at Unity Venture, and Zhang Suyang, Partner at Volcanics Venture, conducted a fruitful collision of ideas around the topic of“AI investment in the primary market at the dawn of a new wave”, actively offered advice and suggestions, and contributed their respective experiences and insights.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/9c62b8356adaf241e7897d474d3a758c.png"/></div>Dr. Lai introduced the key role of capital in the early development of AI companies, drawing on his experience as the founder of an AI-driven drug delivery and drug R&amp;D company. METiS Pharmaceuticals was founded by a group of MIT scientists and a member of the National Academy of Engineering (USA) in 2020. The founding of the company coincided with the outbreak of the COVID-19 pandemic, so all R&amp;D plans were put on hold. As a result, the founding team resolutely moved the core team from the United States to China, as well as their developing work of the platforms. Fortunately, METIS received adequate support from the Hangzhou Municipal Government in terms of start-up funds and laboratory placement, and therefore, quickly settled down in Hangzhou, China. Subsequently, the experimental data was quickly recognized by the capital market. For example, the delivery and transfection efficiency of nanocarriers designed by METiS is more than ten times higher than that of the industry giant Moderna. Meanwhile, METiS has addressed the delivery problems of the lungs, brain, tumors, immune organs, and muscles that are difficult for the industry to overcome. These impressive achievements obtained the support of leading funds, including Sequoia China, 5Y Capital, PICC Capital, and Lightspeed China. Thanks to the support of capital, METiS Pharmaceuticals has grown rapidly in the past three years and is now an innovative biotechnology company that has begun to take shape and focuses on AI-driven drug delivery and drug discovery.<div class="media-wrap image-wrap"><img src="https://oss.metispharmaceuticals.cn/d4ea59defb2e554d181c1428fb4109b9.png"/></div>Dr. Lai is also very optimistic about the future of artificial intelligence technology. In recent years, he has witnessed the &quot;third drug revolution&quot; – the gene therapy drugs based on nucleic acid DNA and RNA codes, following the small molecule targeted drugs and antibody drugs. The mRNA vaccines developed by Moderna and BioNTech performed outstandingly during the COVID-19 pandemic, bringing nucleic acid gene drugs to the masses. The nano-delivery carrier LNP and RNA sequence have proved to be safer than expected, with unexpected drug effects, which has brought a wave of technological and financial benefits to the biopharmaceutical industry. METiS Pharmaceuticals has also joined the wave and quickly deployed the AI-driven nucleic acid delivery system design platform (AiLNP). Thanks to the contributions of the top scientists from MIT, AI technology platforms, and the capital market, METiS has created drug delivery and development capabilities that surpass the industry.Since the decoding of the human genome in 2000, the academic community has accumulated a large number of breakthroughs in molecular biology and genetic coding. These breakthroughs have led to significant progress in the development of nucleic acid-based gene drugs. The next 3-5 years will be a critical moment for the CGT industry, and the key technology to overcome the challenges is drug delivery. Those who will make huge technological breakthroughs and seize the market opportunities will be those who can make nano-delivery carriers that can accurately target and efficiently deliver nucleic acid drugs to disease tissues, and those who can cooperate deeply with major pharmaceutical multinationals.In addition, Dr. Lai looks forward to active support from the supervision authorities for the clinical development of such innovative drugs. He believes that with the efforts of pharmaceutical companies and the investment of capital, China will become a leader in the “third drug revolution” and build a gene drug ecosystem that will promote the R&amp;D of more innovative drugs and bring more good drugs to patients.

从资本助推AI技术发展的角度，和与会者共同探讨了行业发展和机遇，并分享个人经验和见解。

Discussing the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and i

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛

METiS Pharmaceuticals CEO Dr. Chris Lai Attends the 2023 World Artificial Intelligence Conference Financing and Investment Sub-Forum

剂泰医药（METiS）是全球首家以人工智能驱动药物递送和药物发现的生物技术公司，集合人工智能、机器学习和量子模拟等先进技术，旨在实现更有效的创新递送材料设计、候选药物选择和制剂设计、“可编程核酸药物”开发与核酸递送设计。

核心技术

业务|Business

管线|Pipeline

剂泰医药荣登“2023中国生物医药领跑者100”榜单

剂泰医药加盟张江AI新药研发联盟，AI+药物递送助力CGT产业研发进步

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛